BCL2 inhibitor BGB-11417 in R/R B-cell malignancies

 PDF   12/2021

Preliminary Safety and Efficacy Data from Patients (Pts) With Relapsed/Refractory (R/R) B-cell Malignancies Treated with the Novel B-cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Rating

Rate this resource